| Bioactivity | O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a drug to treat type 2 diabetes (T2D) and associated cardiovascular complications [1][2]. | ||||||||||||
| Target | AMPK | ||||||||||||
| In Vivo | O-304 increases glucose uptake in skeletal muscle, reduced β cell stress, and promoted β cell rest in diet-induced obese mice. O-304 reduces fasting plasma glucose levels and homeostasis model assessment of insulin resistance (HOMA-IR) in a proof-of-concept phase IIa clinical trial in type 2 diabetes (T2D) patients on Metformin[2]. | ||||||||||||
| Name | O-304 | ||||||||||||
| CAS | 1261289-04-6 | ||||||||||||
| Formula | C16H11Cl2N3O2S | ||||||||||||
| Molar Mass | 380.25 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Periodic Reporting for period 1-AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes). |
O-304
CAS: 1261289-04-6 F: C16H11Cl2N3O2S W: 380.25
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosp
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.